Imvax
Imvax is a clinical-stage biotechnology company focused on developing personalized, whole tumor-derived immunotherapies for solid tumors, including glioblastoma. Their lead platform, IGV-001, is an autologous tumor cell vaccine designed to induce a broad and durable immune response against tumors. The company is committed to revolutionizing immunotherapy and has a pipeline of clinical trials and research supporting their innovative approach.
Industries
Nr. of Employees
small (1-50)
Imvax
Philadelphia, Pennsylvania, United States, North America
Products
IGV‑001 (autologous tumor‑derived biologic‑device combination)
An autologous therapy comprising irradiated patient tumor cells combined with an antisense oligonucleotide, loaded into an implantable/removable biodiffusion chamber to release antigenic products and induce innate and adaptive immune responses against solid tumors; evaluated in Phase 1/1b and Phase 2b clinical studies for newly diagnosed glioblastoma.
Pipeline of personalized whole tumor‑derived investigational programs
A portfolio approach applying the same tumor‑derived biologic‑device methodology to multiple solid tumor indications (examples referenced in preclinical and pipeline materials include endometrial, ovarian, hepatocellular and other tumor types).
IGV‑001 (autologous tumor‑derived biologic‑device combination)
An autologous therapy comprising irradiated patient tumor cells combined with an antisense oligonucleotide, loaded into an implantable/removable biodiffusion chamber to release antigenic products and induce innate and adaptive immune responses against solid tumors; evaluated in Phase 1/1b and Phase 2b clinical studies for newly diagnosed glioblastoma.
Pipeline of personalized whole tumor‑derived investigational programs
A portfolio approach applying the same tumor‑derived biologic‑device methodology to multiple solid tumor indications (examples referenced in preclinical and pipeline materials include endometrial, ovarian, hepatocellular and other tumor types).
Services
In‑house GMP autologous cell manufacturing
GMP‑level cell processing center for manufacture of investigational and potential commercial supplies of autologous tumor‑derived therapies to support internal clinical programs.
Clinical trial execution for lead oncology programs
Operational management and site coordination for multicenter randomized oncology trials, including enrollment, study drug/device administration logistics, and trial monitoring.
In‑house GMP autologous cell manufacturing
GMP‑level cell processing center for manufacture of investigational and potential commercial supplies of autologous tumor‑derived therapies to support internal clinical programs.
Clinical trial execution for lead oncology programs
Operational management and site coordination for multicenter randomized oncology trials, including enrollment, study drug/device administration logistics, and trial monitoring.
Expertise Areas
- Personalized cancer immunotherapy
- Autologous cell therapy development
- Clinical trial design and execution (oncology)
- Translational immunology and mechanism-of-action studies
Key Technologies
- Autologous whole tumor‑cell vaccines
- Antisense oligonucleotide integration
- Implantable/removable biodiffusion chambers
- Immunogenic cell death assays